Halozyme Therapeutics (HALO) shares were 5% higher premarket Wednesday after the company raised its 2025 adjusted earnings per share and revenue guidance driven by higher royalty revenue and increased product sales from its Xyosted treatment.

The company now expects adjusted earnings per share for 2025 to range from $4.95 to $5.35, up from a previous forecast of $4.45 to $4.85. Analysts polled by FactSet expect full-year adjusted EPS of $4.83.

Halozyme also increased its full-year sales guidance to between $1.15 billion and $1.23 billion from a prior range of $1.1 billion to $1.17 billion. Analysts surveyed by FactSet expect full-year revenue of $1.16 billion.

For 2024, the company reiterated its adjusted earnings per share guidance of $4.00 to $4.20 and revenue guidance of $970 million to $1.02 billion. Analysts polled by FactSet expect 2024 adjusted EPS of $4.14 and revenue of $1 billion.

Halozyme also said it entered into a new $250 million accelerated share repurchase program that is part of a previously disclosed $750 million share repurchase initiative.